MA
VIRX

MUFG Americas’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

MUFG Americas’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-17
Closed -$3K – 1220
2015
Q3 		$3K Sell
17
-2
-11% -$722 ﹤0.01% 1064
2015
Q2 		$12K Buy
19
+3
+19% +$1.59K ﹤0.01% 848
2015
Q1 		$8K Buy
16
+3
+23% +$1.51K ﹤0.01% 956
2014
Q4 		$7K Buy
13
+5
+63% +$2.25K ﹤0.01% 1043
2014
Q3 		$12K Buy
+8
New +$11.6K ﹤0.01% 918

Other funds holding VIRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

MUFG Americas's VIRX Position: Q4 2015 in Review

MUFG Americas sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2015, closing a stake of 17 shares — an estimated $3K sold.

MUFG Americas first reported a position in VIRX in Q3 2014 and held it in 5 quarters. The position peaked at $12K in Q2 2015. 55 funds tracked by Wall St. Rank hold VIRX as of Q4 2015.

  • MUFG Americas reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • MUFG Americas sold 17 Viracta Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $3K.
  • MUFG Americas first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2014 and held it in 5 quarters.
  • MUFG Americas's Viracta Therapeutics, Inc. Common Stock position peaked at $12K in Q2 2015.
  • 55 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2015.

Based on MUFG Americas's 13F filing for Q4 2015, filed 10 Feb 2016.